Serological antibodies in inflammatory bowel disease: A systematic review

Inflammatory Bowel Diseases

Volumn 18, Issue 7, 2012, Pages 1340-1355

  Prideaux, Lani ^a,b   De Cruz, Peter ^a,b   Ng, Siew C ^a,b,c   Kamm, Michael A ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

ACCA; ALCA; AMCA; Anti C; Anti I2; Anti L; Anti OmpC; ASCA; Crohn's disease; pANCA; Serological antibodies; Ulcerative colitis

Indexed keywords

ANTIBODY; BACTERIUM ANTIBODY; CHITIN ANTIBODY; FUNGUS ANTIBODY; LAMINARIBIOSIDE ANTIBODY; LAMINARIN ANTIBODY; MANNOBIOSIDE ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; OUTER MEMBRANE PROTEIN C ANTIBODY; PROTEIN CBIR1 ANTIBODY; SACCHAROMYCES CEREVISIAE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; CROHN DISEASE; DIAGNOSTIC VALUE; ENTERITIS; ETHNIC DIFFERENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INTESTINE SURGERY; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEROPREVALENCE; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

ANTIBODIES; BIOLOGICAL MARKERS; HUMANS; INFLAMMATORY BOWEL DISEASES; PROGNOSIS;

EID: 84858807419     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21903     Document Type: Review

References (202)

1. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5-36.
2. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol. 2006;12:4807-12. (Pubitemid 44323204)
3. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006;55 Suppl 1:i16-35. (Pubitemid 43268291)
4. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. Journal of Crohn's and Colitis. 2010;4:7-27.
5. Price AB. Overlap in the spectrum of non-specific inflammatory bowel disease-'colitis indeterminate'. J Clin Pathol. 1978;31:567-577. (Pubitemid 8358785)
6. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis. 2010;4:28-62.
7. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology. 2006;130:650-656. (Pubitemid 43374514)
8. Freeman HJ. Inflammatory bowel diseases in Indo-Canadians with and without antineutrophil cytoplasmic autoantibodies. Canadian Journal Of Gastroenterology = Journal Canadien De Gastroenterologie. 2000;14:21-26.
9. Broberger O, Perlmann P. Autoantibodies in human ulcerative colitis. J Exp Med. 1959;110:657-74.
10. Rump JA, Scholmerich J, Gross V, et al. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology. 1990;181:406-413.
11. Duerr RH, Targan SR, Landers CJ, Sutherland LR, Shanahan F. Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses. Gastroenterology. 1991;100:1590-1596.
12. Vidrich A, Lee J, James E, Cobb L, Targan S. Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. Journal Of Clinical Immunology. 1995;15:293-299.
13. Eggena M, Cohavy O, Parseghian MH, et al. Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA. J Autoimmun. 2000;14:83-97. (Pubitemid 30080541)
14. Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990;86:202-210. (Pubitemid 20288725)
15. Dotan N, Altstock RT, Schwarz M, Dukler A. Anti-glycan antibodies as biomarkers for diagnosis and prognosis. Lupus. 2006;15:442-450. (Pubitemid 44147091)
16. Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ. 1988;297:1105-11056.
17. McKenzie H, Main J, Pennington CR, Parratt D. Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease. Gut. 1990;31:536-538. (Pubitemid 20185955)
18. Sendid B, Colombel JF, Jacquinot PM, et al. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol. 1996;3:219-226. (Pubitemid 26104780)
19. Standaert-Vitse A, Jouault T, Vandewalle P, et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease. Gastroenterology. 2006;130:1764-1775. (Pubitemid 43668842)
20. Schaffer T, Muller S, Flogerzi B, Seibold-Schmid B, Schoepfer AM, Seibold F. Anti-Saccharomyces cerevisiae mannan antibodies (ASCA) of Crohn's patients crossreact with mannan from other yeast strains, and murine ASCA IgM can be experimentally induced with Candida albicans. Inflamm Bowel Dis. 2007;13:1339-1346. (Pubitemid 350206843)
21. Standaert-Vitse A, Sendid B, Joossens M, et al. Candida albicans colonization and ASCA in familial Crohn's disease. The American Journal Of Gastroenterology. 2009;104:1745-1753.
22. Harrer M, Reinisch W, Dejaco C, et al. Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn's disease? Eur J Gastroenterol Hepatol. 2003;15:1281-1285. (Pubitemid 39049670)
23. Vermeire S, Peeters M, Vlietinck R, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis. 2001;7:8-15.
24. Secondulfo M, De Magistris L, Fiandra R, et al. Intestinal permeability in Crohn's disease patients and their first degree relatives. Digestive and Liver Disease. 2001;33:680-685. (Pubitemid 33107668)
25. Benjamin J, Makharia GK, Joshi YK. Association between intestinal permeability and anti-Saccharomyces cerevisiae antibodies in patients with Crohn's disease. Inflamm Bowel Dis. 2008;14:1610-1611.
26. Dotan I, Fishman S, Dgani Y, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology. 2006;131:366-378. (Pubitemid 44142445)
27. Papp M, Altorjay I, Dotan N, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008;103:665-681. (Pubitemid 351405992)
28. Vermeire S, Joossens S, Peeters M, et al. Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology. 2001;120:827-833. (Pubitemid 32193179)
29. Schwarz M, Spector L, Gargir A, et al. A new kind of carbohydrate array, its use for profiling antiglycan antibodies, and the discovery of a novel human cellulose-binding antibody. Glycobiology. 2003;13:749-754. (Pubitemid 37407104)
30. Seow CH, Stempak JM, Xu W, et al. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol. 2009;104:1426-1434.
31. Lakatos PL, Altorjay I, Szamosi T, et al. Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort. Inflamm Bowel Dis. 2009;15:365-374.
32. Schoepfer AM, Schaffer T, Mueller S, et al. Phenotypic associations of Crohn's disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss Cohort. Inflamm Bowel Dis. 2009;15:1358-1367.
33. Reumaux D, Sendid B, Poulain D, Duthilleul P, Dewit O, Colombel JF. Serological markers in inflammatory bowel diseases. Best Pract Res Clin Gastroenterol. 2003;17:19-35.
34. Sandborn WJ, Loftus EV, Jr., Colombel JF, et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 2001;7:192-201. (Pubitemid 32776511)
35. Lawrance IC, Hall A, Leong R, Pearce C, Murray K. A comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD. Inflamm Bowel Dis. 2005;11:890-897. (Pubitemid 41428847)
36. Homsak E, Micetić-Turk D, Bozic B. Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease: prevalence, characteristics and diagnostic value. Wiener Klinische Wochenschrift. 2010;122 Suppl 2:19-25.
37. Rossato M, Foresta C. Antisperm antibodies in inflammatory bowel disease. Arch Intern Med. 2004;164:2283. (Pubitemid 39452993)
38. Kuwana T, Sato Y, Saka M, et al. Anti-cathepsin G antibodies in the sera of patients with ulcerative colitis. Journal Of Gastroenterology. 2000;35:682-689.
39. Romas E, Paspaliaris B, d'Apice AJ, Elliott PR. Autoantibodies to neutrophil cytoplasmic (ANCA) and endothelial cell surface antigens (AECA) in chronic inflammatory bowel disease. Australian And New Zealand Journal Of Medicine. 1992;22:652-659.
40. Das KM, Dubin R, Nagai T. Isolation and characterization of colonic tissue-bound antibodies from patients with idiopathic ulcerative colitis. Proc Natl Acad Sci U S A. 1978;75:4528-4532. (Pubitemid 9028390)
41. Mallant-Hent RC, Mooij M, von Blomberg BM, Linskens RK, van Bodegraven AA, Savelkoul PH. Correlation between Saccharomyces cerevisiae DNA in intestinal mucosal samples and anti-Saccharomyces cerevisiae antibodies in serum of patients with IBD. World J Gastroenterol. 2006;12:292-297. (Pubitemid 43336930)
42. Sokol H, Seksik P, Rigottier-Gois L, et al. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12:106-111.
43. Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004;53:685-693. (Pubitemid 38561447)
44. Martinez C, Antolin M, Santos J, et al. Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission. Am J Gastroenterol. 2008;103:643-648. (Pubitemid 351405965)
45. Willing B, Halfvarson J, Dicksved J, et al. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm Bowel Dis. 2009;15:653-660.
46. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004;126:414-424. (Pubitemid 38182298)
47. Vecchi M, Spina L, Cavallaro F, Pastorelli L. Do antibodies have a role in IBD pathogenesis? Inflamm Bowel Dis. 2008;14 Suppl 2:S95-S96.
48. Rieder F, Schleder S, Wolf A, et al. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. Inflamm Bowel Dis. 2010;16:263-274.
49. Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998;42:788-791. (Pubitemid 28277217)
50. Panaccione R, Sandborn WJ. Is antibody testing for inflammatory bowel disease clinically useful? Gastroenterology. 1999;116:1001-2; discussion 2-3.
51. Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol. 2008;6:1105-1111.
52. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007;56:1394-1403. (Pubitemid 47517833)
53. Stewenius, Adnerhill I, Ekelund GR, et al. Operations in unselected patients with ulcerative colitis and indeterminate colitis. A long-term follow-up study. Eur J Surg. 1996;162:131-137.
54. Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology. 2002;122:1242-1247. (Pubitemid 34465166)
55. Moum B, Ekbom A, Vatn MH, et al. Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway. Gut. 1997;40:328-332. (Pubitemid 27145644)
56. Henriksen M, Jahnsen J, Lygren I, et al. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). ScandJGastroenterol. 2007;42:602-610. (Pubitemid 46633816)
57. Stordal K, Jahnsen J, Bentsen BS, Moum B. Pediatric inflammatory bowel disease in southeastern Norway: a five-year follow-up study. Digestion. 2004;70:226-230. (Pubitemid 40522767)
58. Melmed GY, Elashoff R, Chen GC, et al. Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study. Clin Gastroenterol Hepatol. 2007;5:602-608; quiz 525.
59. Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology. 2002;123:689-699. (Pubitemid 34977074)
60. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005;128:2020-2028. (Pubitemid 40824710)
61. Rieder F, Schleder S, Wolf A, et al. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: A cohort study. Inflamm Bowel Dis. 2009.
62. Desir B, Amre DK, Lu SE, et al. Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:139-146. (Pubitemid 38180468)
63. Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005;54:1232-1236. (Pubitemid 41192480)
64. Muller S, Styner M, Seibold-Schmid B, et al. Anti-Saccharomyces cerevisiae antibody titers are stable over time in Crohn's patients and are not inducible in murine models of colitis. World J Gastroenterol. 2005;11:6988-6994. (Pubitemid 43126058)
65. Roozendaal C, Pogány K, Hummel EJ, et al. Titres of anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease are not related to disease activity. QJM: Monthly Journal Of The Association Of Physicians. 1999;92:651-658. (Pubitemid 29515871)
66. Vecchi M, Bianchi MB, Calabresi C, Meucci G, Tatarella M, de Franchis R. Long-term observation of the perinuclear anti-neutrophil cytoplasmic antibody status in ulcerative colitis patients. Scand J Gastroenterol. 1998;33:170-173. (Pubitemid 28098232)
67. Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut. 1984;25:665-672. (Pubitemid 14122134)
68. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004;60:505-512. (Pubitemid 39311530)
69. Modigliani R. Endoscopic severity index for Crohn's disease. Gastrointest Endosc. 1990;36:637.
70. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005;128:862-869. (Pubitemid 40523539)
71. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777-782. (Pubitemid 33096034)
72. Markowitz J, Kugathasan S, Dubinsky M, et al. Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology? Inflamm Bowel Dis. 2009;15:714-719.
73. Papadakis KA, Yang H, Ippoliti A, et al. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis. 2007;13:524-530. (Pubitemid 46799635)
74. Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000;47:487-496.
75. Papp M, Altorjay I, Norman GL, et al. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflamm Bowel Dis. 2007;13:984-992. (Pubitemid 47309970)
76. Simondi D, Mengozzi G, Betteto S, et al. Antiglycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:645-651. (Pubitemid 351742981)
77. Halfvarson J, Standaert-Vitse A, Jarnerot G, et al. Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease. Gut. 2005;54:1237-1243. (Pubitemid 41192481)
78. Malickova K, Lakatos PL, Bortlik M, Komarek V, Janatkova I, Lukas M. Anticarbohydrate antibodies as markers of inflammatory bowel disease in a Central European cohort. Eur J Gastroenterol Hepatol. 2010;22:144-150.
79. Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004;99:2376-2384. (Pubitemid 40039369)
80. Smith BR, Arnott ID, Drummond HE, Nimmo ER, Satsangi J. Disease location, anti-Saccharomyces cerevisiae antibody, and NOD2/CARD15 genotype influence the progression of disease behavior in Crohn's disease. Inflamm Bowel Dis. 2004;10:521-528. (Pubitemid 39276458)
81. Rejchrt S, Drahosova M, Kopacova M, et al. Antilaminaribioside and antichitobioside antibodies in inflammatory bowel disease. Folia Microbiol (Praha). 2008;53:373-376.
82. Solberg IC, Lygren I, Cvancarova M, et al. Predictive value of serologic markers in a population-based Norwegian cohort with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:406-414.
83. Linskens RK, Mallant-Hent RC, Groothuismink ZM, et al. Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods. Eur J Gastroenterol Hepatol. 2002;14:1013-1018.
84. Klebl FH, Bataille F, Bertea CR, et al. Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease. Inflamm Bowel Dis. 2003;9:302-307. (Pubitemid 37161749)
85. Russell RK, Ip B, Aldhous MC, et al. Anti-Saccharomyces cerevisiae antibodies status is associated with oral involvement and disease severity in Crohn disease. J Pediatr Gastroenterol Nutr. 2009;48:161-167.
86. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflammatory Bowel Diseases. 2002;8:244-250. (Pubitemid 34784976)
87. Vasiliauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology. 1996;110:1810-1819. (Pubitemid 26169219)
88. Freeman HJ. Atypical perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease. Can J Gastroenterol. 1997;11:689-693. (Pubitemid 28036944)
89. Dubinsky MC, Lin Y-C, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. The American Journal Of Gastroenterology. 2006;101:360-367. (Pubitemid 43381681)
90. Amre DK, Lu SE, Costea F, Seidman EG. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol. 2006;101:645-652. (Pubitemid 43340944)
91. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 1998;115:822-829. (Pubitemid 28452928)
92. Oshitani N, Hato F, Matsumoto T, et al. Decreased anti-Saccharomyces cerevisiae antibody titer by mesalazine in patients with Crohn's disease. J Gastroenterol Hepatol. 2000;15:1400-1403. (Pubitemid 32052913)
93. Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol. 2004;99:2235-2241. (Pubitemid 39524716)
94. Cambridge G, Rampton DS, Stevens TR, McCarthy DA, Kamm M, Leaker B. Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1992;33:668-674.
95. Taddei C, Audrain MA, Reumaux D, et al. Alpha1-antitrypsin phenotypes and anti-neutrophil cytoplasmic auto-antibodies in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1999;11:1293-1298. (Pubitemid 29531354)
96. Castellino F, Rosina F, Bansi DS, et al. Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease: do they recognize different subsets of a heterogeneous disease? European Journal Of Gastroenterology & Hepatology. 1995;7:859-864.
97. Canani RB, Romano MT, Greco L, et al. Effects of disease activity on anti-Saccharomyces cerevisiae antibodies: implications for diagnosis and follow-up of children with Crohn's disease. Inflamm Bowel Dis. 2004;10:234-239. (Pubitemid 38618252)
98. Esters N, Vermeire S, Joossens S, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol. 2002;97:1458-1462. (Pubitemid 34664792)
99. Taylor KD, Plevy SE, Yang H, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology. 2001;120:1347-1355. (Pubitemid 32322308)
100. Arnott IDR, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Alimentary Pharmacology & Therapeutics. 2003;17:1451-1457. (Pubitemid 36831435)
101. Mow WS, Landers CJ, Steinhart AH, et al. High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study. Dig Dis Sci. 2004;49:1280-1286. (Pubitemid 39178101)
102. Oudkerk Pool M, Ellerbroek PM, Ridwan BU, et al. Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment. Gut. 1993;34:46-50. (Pubitemid 23015949)
103. Teml A, Kratzer V, Schneider B, et al. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol. 2003;98:2226-2231. (Pubitemid 37305363)
104. Lonnkvist MH, Befrits R, Lundberg JO, et al. Infliximab in clinical routine: Experience with Crohn's disease and biomarkers of inflammation over 5 years. European Journal of Gastroenterology and Hepatology. 2009;21:1168-1176.
105. Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut. 2004;53:1117-1122. (Pubitemid 38961964)
106. Spivak J, Landers CJ, Vasiliauskas EA, et al. Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease. Inflamm Bowel Dis. 2006;12:1122-1130. (Pubitemid 44847469)
107. Odes S, Friger M, Vardi H, et al. Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn's disease patients: a project of the European Collaborative Study Group on Inflammatory Bowel Disease. Inflamm Bowel Dis. 2007;13:874-881. (Pubitemid 47203865)
108. Satsangi J, Landers CJ, Welsh KI, Koss K, Targan S, Jewell DP. The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease. Inflamm Bowel Dis. 1998;4:18-26. (Pubitemid 128699832)
109. Reumaux D, Colombel JF, Masy E, et al. Anti-neutrophil cytoplasmic auto-antibodies (ANCA) in ulcerative colitis (UC): no relationship with disease activity. Inflamm Bowel Dis. 2000;6:270-274.
110. Olives JP, Breton A, Hugot JP, et al. Antineutrophil cytoplasmic antibodies in children with inflammatory bowel disease: prevalence and diagnostic value. J Pediatr Gastroenterol Nutr. 1997;25:142-148. (Pubitemid 27311375)
111. Lindgren S, Floren CH, Lindhagen T, Starck M, Stewenius J, Nassberger L. Low prevalence of anti-neutrophil cytoplasmic antibodies in ulcerative colitis patients with long-term remission. Eur J Gastroenterol Hepatol. 1995;7:563-568.
112. Aitola P, Miettinen A, Mattila A, Matikainen M, Soppi E. Effect of proctocolectomy on serum antineutrophil cytoplasmic antibodies in patients with chronic ulcerative colitis. Journal Of Clinical Pathology. 1995;48:645-647.
113. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc. 1996;71:431-436. (Pubitemid 26144146)
114. Hoie O, Aamodt G, Vermeire S, et al. Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years. Journal of Crohn's and Colitis. 2008;2:114-122. (Pubitemid 351672116)
115. Vecchi M, Bianchi MB, Sinico RA, et al. Antibodies to neutrophil cytoplasm in Italian patients with ulcerative colitis: sensitivity, specificity and recognition of putative antigens. Digestion. 1994;55:34-39. (Pubitemid 24014638)
116. Jürgens M, Laubender RP, Hartl F, et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. The American Journal Of Gastroenterology. 2010;105:1811-1819.
117. Dubinsky MC, Mei L, Friedman M, et al. Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2010;16: 1357-1366.
118. Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123-128. (Pubitemid 46806219)
119. Dendrinos KG, Becker JM, Stucchi AF, Saubermann LJ, LaMorte W, Farraye FA. Anti-Saccharomyces cerevisiae antibodies are associated with the development of postoperative fistulas following ileal pouch-anal anastomosis. J Gastrointest Surg. 2006;10:1060-1064. (Pubitemid 44037475)
120. Melmed GY, Fleshner PR, Bardakcioglu O, et al. Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2008;51:100-108.
121. Verbeeten D, Milgrom R, Xu W, et al. Serum ASCA and smoking status are associated with a crohn's disease-like phenotype after pelvic pouch surgery for ulcerative colitis. Canadian Journal of Gastroenterology. 2009;23.
122. Evers EA, Pfefferkorn MD, Steiner SJ. Factors predictive of Crohn disease following colectomy in medically refractory pediatric colitis. J Pediatr Gastroenterol Nutr. 2009;48:283-286.
123. Hui T, Landers C, Vasiliauskas E, et al. Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation. Dis Colon Rectum. 2005;48:1254-1262.
124. Vecchi M, Sinico A, Bianchi MB, et al. Recognition of bactericidal/permeability-increasing protein by perinuclear anti-neutrophil cytoplasmic antibody-positive sera from ulcerative colitis patients: prevalence and clinical significance. Scandinavian Journal Of Gastroenterology. 1998;33:1284-1288. (Pubitemid 29046534)
125. Yang P, Oresland T, Järnerot G, Hultén L, Danielsson D. Perinuclear antineutrophil cytoplasmic antibody in pouchitis after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Scandinavian Journal Of Gastroenterology. 1996;31:594-598. (Pubitemid 26196141)
126. Vecchi M, Gionchetti P, Bianchi MB, et al. p-ANCA and development of pouchitis in ulcerative colitis patients after proctocolectomy and ileoanal pouch anastomosis. Lancet. 1994;344:886-887. (Pubitemid 24290397)
127. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. The American Journal Of Gastroenterology. 1995;90:740-747.
128. Patel RT, Stokes R, Birch D, Ibbotson J, Keighley MR. Influence of total colectomy on serum antineutrophil cytoplasmic antibodies in inflammatory bowel disease. The British Journal Of Surgery. 1994;81:724-726. (Pubitemid 24192110)
129. Aisenberg J, Legnani PE, Nilubol N, et al. Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients. Am J Gastroenterol. 2004;99:432-441. (Pubitemid 38524119)
130. Ferrante M, Declerck S, Coopmans T, et al. Development of pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis: A role for serological markers and microbial pattern recognition receptor genes. Journal of Crohn's and Colitis. 2008;2:142-151. (Pubitemid 351672120)
131. Kuisma J, Jarvinen H, Kahri A, Farkkila M. Factors associated with disease activity of pouchitis after surgery for ulcerative colitis. Scandinavian Journal Of Gastroenterology. 2004;39:544-548. (Pubitemid 38916259)
132. Fleshner PR, Vasiliauskas EA, Kam LY, et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut. 2001;49:671-677. (Pubitemid 32989204)
133. Fleshner P, Ippoliti A, Dubinsky M, et al. Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2008;6:561-568.
134. Devlin SM, Yang H, Ippoliti A, et al. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology. 2007;132:576-586. (Pubitemid 46274655)
135. Cruyssen BV, Peeters H, Hoffman IE, et al. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients. Clin Exp Immunol. 2005;140:354-359. (Pubitemid 40559164)
136. Nisihara RM, de Carvalho WB, da Rosa Utiyama SR, Amarante H, Baptista ML. Diagnostic Role and Clinical Association of ASCA and ANCA in Brazilian Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2009.
137. Bouzid D, Haddouk S, Amouri A, et al. Diagnostic value and clinical significance of serological markers in Tunisian patients with inflammatory bowel diseases. Annales de Biologie Clinique. 2010;68:577-583.
138. Bahari A, Aarabi M, Aarabi M, et al. Diagnostic value of antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibody in Iranian patients with inflammatory bowel disease. Acta Gastro-Enterologica Belgica. 2009;72:301-305.
139. Lawrance IC, Murray K, Hall A, Sung JJ, Leong R. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients. Am J Gastroenterol. 2004;99:2186-2194. (Pubitemid 39524710)
140. Hisabe T, Matsui T, Sakurai T, et al. Anti-Saccharomyces cerevisiae antibodies in Japanese patients with inflammatory bowel disease: diagnostic accuracy and clinical value. J Gastroenterol. 2003;38:121-126. (Pubitemid 36372285)
141. Marrakchi R, Bougatef K, Moussa A, et al. 3020insC insertion in NOD2/CARD15 gene, a prevalent variant associated with anti-Saccharomyces cerevisiae antibodies and ileal location of Crohn's disease in Tunisian population. Inflamm Res. 2009;58:218-223.
142. Kim BG, Kim YS, Kim JS, Jung HC, Song IS. Diagnostic role of anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic antibodies in patients with inflammatory bowel disease. Dis Colon Rectum. 2002;45:1062-1069.
143. Kim BC, Park S, Han J, Kim JH, Kim TI, Kim WH. Clinical significance of anti-Saccharomyces cerevisiae antibody (ASCA) in Korean patients with Crohn's disease and its relationship to the disease clinical course. Dig Liver Dis. 2007;39:610-616. (Pubitemid 46888207)
144. Preda CM, Diculescu M, Mirea V, et al. Significance of anti-sacharomices cerevisiae antibodies (ASCA) in patients with inflammatory bowel diseases in Romania. Rom J Gastroenterol. 2005;14:23-36.
145. Koutroubakis IE, Drygiannakis D, Tsirogianni A, et al. Antiglycan antibodies in Greek patients with inflammatory bowel disease. Dig Dis Sci. 2011;56:845-852.
146. Dassopoulos T, Nguyen GC, Talor MV, et al. NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn's disease in African Americans. The American Journal Of Gastroenterology. 2010;105:378-386.
147. Zhou F, Xia B, Wang F, et al. The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease in mainland China. Clinica Chimica Acta; International Journal Of Clinical Chemistry. 2010;411:1461-1465.
148. Kaneko K, Suzuki Y, Shimizu T, Yamashiro Y, Yabuta K, Lifschitz CH. Anti-neutrophil cytoplasmic antibodies in Japanese children with ulcerative colitis. Journal Of Paediatrics And Child Health. 1995;31:336-338.
149. Lee JH, Cheon JH, Kim ES, et al. The Prevalence and Clinical Significance of Perinuclear Anti-neutrophil Cytoplasmic Antibody in Korean Patients with Ulcerative Colitis. Dig Dis Sci. 2009.
150. Osangthamnont C, Manatsathit S, Pongprasopchai S, et al. Antibodies to neutrophil cytoplasma in patients with ulcerative colitis and their first-degree relatives in Thailand. Journal Of Gastroenterology And Hepatology. 2001;16:866-871. (Pubitemid 32868630)
151. Preda CM, Vermeire S, Rutgeerts P, et al. Prevalence and significance of perinuclear anti-neutrophil antibodies (pANCA) in Romanian patients with Crohn's disease and ulcerative colitis. Rom J Gastroenterol. 2005;14:357-360. (Pubitemid 43027124)
152. Yamamoto-Furusho JK, Takahashi-Monroy T, Vergara-Fernandez O, Reyes E, Uscanga L. Perinuclear anti-neutrophil cytoplasmic antibodies (p-anca) in chronic ulcerative colitis: experience in a Mexican institution. World J Gastroenterol. 2006;12:3406-3409. (Pubitemid 43933787)
153. Kull K, Salupere R, Uibo R, Ots M, Salupere V. Antineutrophil cytoplasmic antibodies in Estonian patients with inflammatory bowel disease. Prevalence and diagnostic role. Hepato-Gastroenterology. 1998;45:2132-2137. (Pubitemid 29055791)
154. Annese V, Andreoli A, Andriulli A, et al. Familial expression of anti- Saccharomyces cerevisiae Mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study. Am J Gastroenterol. 2001;96:2407-2412. (Pubitemid 32769203)
155. Sendid B, Quinton JF, Charrier G, et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol. 1998;93:1306-1310. (Pubitemid 29076932)
156. Seibold F, Stich O, Hufnagl R, Kamil S, Scheurlen M. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study. Scand J Gastroenterol. 2001;36:196-201. (Pubitemid 32183432)
157. Glas J, Torok HP, Vilsmaier F, Herbinger KH, Hoelscher M, Folwaczny C. Anti-saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease and their first-degree relatives: potential clinical value. Digestion. 2002;66:173-177. (Pubitemid 36096844)
158. Sutton CL, Yang H, Li Z, Rotter JI, Targan SR, Braun J. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut. 2000;46:58-63. (Pubitemid 30307678)
159. Hadrich I, Vandewalle P, Cheikhrouhou F, et al. Ethnic and sociocultural specificities in Tunisia have no impact on the prevalence of anti-Saccharomyces cerevisiae antibodies in Crohn's disease patients, their relatives or associated clinical factors. Scand J Gastroenterol. 2007;42:717-725. (Pubitemid 46763585)
160. Seibold F, Slametschka D, Gregor M, Weber P. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 1994;107:532-536. (Pubitemid 24233330)
161. Shanahan F, Duerr RH, Rotter JI, et al. Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterology. 1992;103:456-461.
162. Lee JC, Lennard-Jones JE, Cambridge G. Antineutrophil antibodies in familial inflammatory bowel disease. Gastroenterology. 1995;108:428-433.
163. Folwaczny C, Noehl N, Endres SP, Loeschke K, Fricke H. Antineutrophil and pancreatic autoantibodies in first-degree relatives of patients with inflammatory bowel disease. Scandinavian Journal Of Gastroenterology. 1998;33:523-528. (Pubitemid 28277253)
164. Bansi DS, Lo S, Chapman RW, Fleming KA. Absence of antineutrophil cytoplasmic antibodies in relatives of UK patients with primary sclerosing cholangitis and ulcerative colitis. Eur J Gastroenterol Hepatol. 1996;8:111-116. (Pubitemid 26130231)
165. Reumaux D, Delecourt L, Colombel JF, Noel LH, Duthilleul P, Cortot A. Anti-neutrophil cytoplasmic autoantibodies in relatives of patients with ulcerative colitis. Gastroenterology. 1992;103:1706.
166. Papo M, Quer JC, Pastor RM, et al. Antineutrophil cytoplasmic antibodies in relatives of patients with inflammatory bowel disease. The American Journal Of Gastroenterology. 1996;91:1512-1515. (Pubitemid 26269161)
167. Yang P, Järnerot G, Danielsson D, Tysk C, Lindberg E. P-ANCA in monozygotic twins with inflammatory bowel disease. Gut. 1995;36:887-890.
168. Mei L, Targan SR, Landers CJ, et al. Familial expression of anti- Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterology. 2006;130:1078-1085.
169. Torok HP, Glas J, Hollay HC, et al. Serum antibodies in first-degree relatives of patients with IBD: a marker of disease susceptibility? A follow-up pilot-study after 7 years. Digestion. 2005;72:119-123. (Pubitemid 41507271)
170. Joossens M, Van Steen K, Branche J, et al. Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's disease. Inflamm Bowel Dis. 2010;16:58-67.
171. Walker LJ, Aldhous MC, Drummond HE, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol. 2004;135:490-496. (Pubitemid 38297152)
172. Dassopoulos T, Frangakis C, Cruz-Correa M, et al. Antibodies to saccharomyces cerevisiae in Crohn's disease: higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease. Inflamm Bowel Dis. 2007;13:143-151. (Pubitemid 46806222)
173. Henckaerts L, Pierik M, Joossens M, Ferrante M, Rutgeerts P, Vermeire S. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut. 2007;56:1536-1542. (Pubitemid 350033192)
174. Ippoliti A, Devlin S, Mei L, et al. Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease. Inflammatory Bowel Diseases. 2010;16:1279-1285.
175. Vander Cruyssen B, Peeters H, Hoffman IEA, et al. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients. Clinical And Experimental Immunology. 2005;140:354-359. (Pubitemid 40559164)
176. Lakatos PL, Altorjay I, Mandi Y, et al. Interaction between seroreactivity to microbial antigens and genetics in Crohn's disease: Is there a role for defensins? Tissue Antigens. 2008;71:552-559. (Pubitemid 351697252)
177. Iltanen S, Tervo L, Halttunen T, et al. Elevated serum anti-I2 and anti-OmpW antibody levels in children with IBD. Inflamm Bowel Dis. 2006;12:389-394.
178. Joossens S, Colombel JF, Landers C, et al. Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis. Gut. 2006;55:1667-1669. (Pubitemid 44629225)
179. Hoffenberg EJ, Fidanza S, Sauaia A. Serologic testing for inflammatory bowel disease. J Pediatr. 1999;134:447-452. (Pubitemid 30180626)
180. Ashorn S, Honkanen T, Kolho KL, et al. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:199-205.
181. Klebl FH, Bataille F, Hofstadter F, Herfarth H, Scholmerich J, Rogler G. Optimising the diagnostic value of anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn's disease. Int J Colorectal Dis. 2004;19:319-324. (Pubitemid 38868297)
182. Riis L, Vind I, Vermeire S, et al. The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Inflamm Bowel Dis. 2007;13:24-32. (Pubitemid 46080006)
183. Elitsur Y, Lawrence Z, Tolaymat N. The diagnostic accuracy of serologic markers in children with IBD: the West Virginia experience. J Clin Gastroenterol. 2005;39:670-673. (Pubitemid 41177084)
184. Cohavy O, Bruckner D, Gordon LK, et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun. 2000;68:1542-1548. (Pubitemid 30108556)
185. Wei B, Huang T, Dalwadi H, Sutton CL, Bruckner D, Braun J. Pseudomonas fluorescens encodes the Crohn's disease-associated I2 sequence and T-cell superantigen. Infect Immun. 2002;70:6567-6575. (Pubitemid 35387882)
186. Sutton CL, Kim J, Yamane A, et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology. 2000;119:23-31. (Pubitemid 30452575)
187. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest. 2004;113:1296-1306. (Pubitemid 39069929)
188. Oberstadt K, Schaedel W, Weber M, Classen M, Deusch K. PANCA as a differential diagnostic marker in inflammatory bowel disease. Advances In Experimental Medicine And Biology. 1995;371B:1313-1316.
189. Proujansky R, Fawcett PT, Gibney KM, Treem WR, Hyams JS. Examination of anti-neutrophil cytoplasmic antibodies in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1993;17:193-197. (Pubitemid 23249801)
190. Winter HS, Landers CJ, Winkelstein A, Vidrich A, Targan SR. Antineutrophil cytoplasmic antibodies in children with ulcerative colitis. J Pediatr. 1994;125:707-711. (Pubitemid 24350178)
191. Joossens S, Pierik M, Rector A, et al. Mannan binding lectin (MBL) gene polymorphisms are not associated with anti-Saccharomyces cerevisiae (ASCA) in patients with Crohn's disease. Gut. 2006;55:746.
192. Freeman H, Roeck B, Devine D, Carter C. Prospective evaluation of neutrophil autoantibodies in 500 consecutive patients with inflammatory bowel disease. Can J Gastroenterol. 1997;11:203-207. (Pubitemid 27197156)
193. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001;96:730-734. (Pubitemid 32240723)
194. Kaila B, Orr K, Bernstein CN. The anti-Saccharomyces cerevisiae antibody assay in a province-wide practice: accurate in identifying cases of Crohn's disease and predicting inflammatory disease. Can J Gastroenterol. 2005;19:717-721. (Pubitemid 43125124)
195. Reese GE, Constantinides VA, Simillis C. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol. 2006;101:2410-2422. (Pubitemid 44477569)
196. Anand V, Russell AS, Tsuyuki R, Fedorak R. Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn's disease and ulcerative colitis. Can J Gastroenterol. 2008;22:33-36. (Pubitemid 351385649)
197. Halme L, Turunen U, Helio T, et al. Familial and sporadic inflammatory bowel disease: comparison of clinical features and serological markers in a genetically homogeneous population. Scand J Gastroenterol. 2002;37:692-698. (Pubitemid 34620932)
198. Yasuda N, Thomas P, Ellis H, Herbst F, Nicholls J, Ciclitira P. Perinuclear anti-neutrophil cytoplasmic antibodies in ulcerative colitis after restorative proctocolectomy do not correlate with the presence of pouchitis. Scandinavian Journal Of Gastroenterology. 1998;33:509-513. (Pubitemid 28277251)
199. Kaditis AG, Perrault J, Sandborn WJ, Landers CJ, Zinsmeister AR, Targan SR. Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouch-anal anastomosis for ulcerative colitis. Journal Of Pediatric Gastroenterology And Nutrition. 1998;26:386-392. (Pubitemid 28160685)
200. Esteve M, Mallolas J, Klaassen J, et al. Factors related to the presence of IgA class antineutrophil cytoplasmic antibodies in ulcerative colitis. The American Journal Of Gastroenterology. 1998;93:615-618. (Pubitemid 29081013)
201. Esteve M, Mallolas J, Klaassen J, et al. Antineutrophil cytoplasmic antibodies in sera from colectomised ulcerative colitis patients and its relation to the presence of pouchitis. Gut. 1996;38:894-898. (Pubitemid 26231775)
202. Aisenberg J, Wagreich J, Shim J, et al. Perinuclear anti-neutrophil cytoplasmic antibody and refractory pouchitis. A case-control study. Digestive Diseases And Sciences. 1995;40:1866-1872.